GSK Pushes First-in-Class Antibiotic for Uncomplicated UTI By March 26, the FDA is scheduled to release its verdict on GSK’s investigational antibiotic gepotidacin for the treatment of uncomplicated ...

GSK reported core earnings of 59 cents per American depositary ... Juluca rose 10% while Dovato was up 27% in the quarter. Rukobia sales rose 46% in the quarter. Sales of new long-acting medicines, ...

GSK reported core earnings of 59 cents per American ... Juluca rose 10% while Dovato was up 27% in the quarter. Rukobia sales rose 46% in the quarter. Sales of new long-acting medicines, Cabenuva ...

The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...

Multinational pharmaceutical company GSK’s commitment to invest up to $800 million in its facility near Marietta may have gone elsewhere without tax incentives approved by local officials last year.